Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate. A randomised phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high risk, clinically localised prostate cancer.
DASL-HiCaP is a randomised phase 3 study aiming to demonstrate that the addition of a new oral hormonal therapy, darolutamide, to the standard radiation therapy and testosterone suppression, improves the outcomes of men with localised high-risk prostate cancer.
Primary Sponsor
Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)
Collaborating Groups
Trans Tasman Radiation Oncology Group (TROG), NHMRC Clinical Trials Centre
Accrual Target
1100
Final Accrual
1100
Trial Chairperson
Prof Christopher Sweeney and Assoc/Prof Tamim Niazi
Trial Contact
dasl.study@sydney.edu.au
Clinical Trial Registration
Related Post
24 September, 2025
Prostate Cancer Month: Focus on the TROG Genitourinary Working Party
To mark Prostate Cancer Month in September, we asked
24 September, 2025
TROG members and staff celebrate World Radiotherapy Awareness Day
LATEST NEWS: 24 September 2025 TROG Cancer Research staff